Androski Lindsay 4
4 · Arbutus Biopharma Corp · Filed Mar 20, 2025
Insider Transaction Report
Form 4
Androski Lindsay
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-03-18+310,422→ 310,422 totalExercise: $3.20Exp: 2035-03-18→ Common Shares (310,422 underlying)
Footnotes (2)
- [F1]Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
- [F2]This option vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.